Assessing the impact of switching to the Tobacco Heating System on cardiovascular diseases: Translating basic science into clinical benefit Posters posters ClinicalPre-clinical Toxicologyclinicalpreclinicaltoxicology Oct 28, 2020 20201028 /content/dam/pmiscience/default-fallback-thumbnails/publication/pmi-science-laboratory-work-in-lab-3840x2160.jpg
      Posters

      Assessing the impact of switching to the Tobacco Heating System on cardiovascular diseases: Translating basic science into clinical benefit

      Baker, G.; de la Bourdonnaye, G.; Elamin, A.; Goujon, C.; Haziza, C.; Heremans, A.; Hoeng, J.; Ivanov, N.; Luedicke, F.; Maeder, S.; Phillips, B.; Picavet, P.; Pouly, S.; Poussin, C.; Pratte, P.; Tran, C. T.; Vanscheeuwijck, P.; Peitsch, M.
      Conference date
      Oct 28, 2020
      Conference name
      Printemps de la Cardiologie
      Link to more information
      Topic
      Summary

      No abstract available.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.